E-cigarette Sales Surge by Almost 50%: CDC Data

Jun.25.2023
E-cigarette Sales Surge by Almost 50%: CDC Data
CDC data shows e-cigarette sales increased nearly 50% in three years, led by non-tobacco flavors. Sales of disposable e-cigarettes surpassed pod systems.

According to CBS News, data released by the U.S. Centers for Disease Control and Prevention (CDC) shows that e-cigarette sales have grown by nearly 50% over the past three years, increasing from 15.5 million in January 2020 to 22.7 million in December 2022.


These data come from an analysis by the Centers for Disease Control and Prevention of data from market research companies. The analysis was published in the agency's "Morbidity and Mortality Weekly Report.


One-time-use sales surpass replaceable magazine sales.


Fatma Romeh, the Chief Market Analyst at CDC, stated in a declaration that...


The significant increase in e-cigarette sales from 2020 to 2022 is primarily driven by the growth of non-tobacco flavored e-cigarettes, such as the dominance of mint flavor in the prefilled pod market and the leading position of fruit and candy flavors in the disposable e-cigarette market.


According to the national youth tobacco survey data released in 2022, more than 80% of middle and high school students use e-cigarettes with fruit or mint flavors, as pointed out by Romei.


According to data, even though disposable e-cigarettes accounted for less than a quarter of total sales in January 2020, by March 2022 disposable e-cigarette sales surpassed pod system sales.


From January 2020 to December 2022, the unit share of pod systems decreased from 75.2% of total sales to 48.0%, while the unit share of disposable e-cigarettes increased from 24.7% to 51.8%.


Sales of e-cigarettes | Image source: Centers for Disease Control and Prevention in the United States


Sales volume of pod systems | Image source: Centers for Disease Control and Prevention in the United States.


Sales of disposable e-cigarettes | Image source: Centers for Disease Control and Prevention in the United States.


The total number of e-cigarette brands in the market has increased by 46.2%.


According to data, the number of e-cigarette brands in the United States market is continually increasing. During the CDC study, the total number of e-cigarette brands in the US market increased by 46.2%, from 184 to 269.


Deirdre Lawrence Kittner, the Director of Smoking and Health Office at the CDC, stated in a release:


The sharp rise in e-cigarette use among teenagers in 2017 and 2018, fueled largely by JUUL, highlights the rapid evolution of sales and use patterns in the e-cigarette industry.


The overall sales growth of e-cigarettes has slowed down.


According to data, total sales increased by 67.2% from January 2020 to May 2022, rising from 15.5 million units per period to 25.9 million units. However, from May 2022 to December 2022, total sales decreased by 12.3%.


Even though overall monthly sales have been decreasing since May 2022, sales are still millions higher compared to early 2020. The CDC attributes the recent decline to several factors, including the efforts of health departments to regulate the sales of nicotine products.


At the national level, the FDA has taken multiple measures this year in an effort to curb unauthorized sales of e-cigarettes.


Director of the Center for Tobacco Products (CTP) at the FDA, Brian King, stated in a declaration that:


All participants in the supply chain, including retailers, have a responsibility to prevent illegal e-cigarettes from being placed on the market.


A previous CDC study report analyzed that the comprehensive flavor ban in Massachusetts resulted in a sharp decline of 94% in the sales of flavored e-cigarettes in the state.


It is worth noting that more and more state and local governments in the United States are also attempting to impose restrictions on the sale of flavored e-cigarettes.


As of December 31, 2022, seven states (California, Maryland, Massachusetts, New Jersey, New York, Rhode Island, and Utah) and 378 jurisdictions (including counties, cities, towns, and villages) have implemented some form of restriction on flavored electronic products.


The CDC acknowledged that other factors may also contribute to the sales slowdown, including the increase in high-dose or high-volume disposable e-cigarettes purchased at one time, resulting in more or stronger doses each time.


Moreover, this data is limited to the sales performance of traditional brick-and-mortar retailers. This suggests that some sales may not have actually declined, but instead shifted elsewhere, such as online orders or specialized e-cigarette stores not included in the company's sales data.


References:


Health officials have raised concerns about the surge in e-cigarette sales, which have coincided with a rise in calls to poison control centers.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
AIR’s first half-year results as a listed company offer a new test of how far a traditional hookah business can transform. H1 2026 revenue rose 3.7%, even as Flavored Shisha Molasses shipments fell 9%, with pricing and mix supporting growth. Traditional shisha still generates almost all revenue, while OOKA, Crown Switch, Greentank and U.S. regulatory spending point to accelerating diversification. The next test is whether those investments can become a second business of meaningful scale and profitability.
Capital Markets
Aug.21
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11